Safety and Efficacy of Intraperitoneal Injection of METR-NK Cells as Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer

• Status: RECRUITING
• Trial end date: 2026-12-31

Summary

The goal of this type of clinical trial study is to evaluate the safety and efficacy of metabolic remodeling nature killer cells as neoadjuvant therapy in newly diagnosed patients with advanced ovarian cancer

• Phase: PHASE1

Details

• Lead Sponsor: Anhui Provincial Cancer Hospital
• Collaborator: Anhui Kecheng intelligent health technology Co., LTD